5-alpha-reductase deficiency pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
Line 3: Line 3:
{{CMG}}
{{CMG}}
==Overview==
==Overview==
The [[5-alpha reductase]] [[enzyme]] is responsible for converting [[testosterone]] to [[dihydrotestosterone]] (DHT) which is a more potent form playing major roles in [[male]] [[sexual development]].
While [[Testosterone]] leads the development of [[internal]] [[male genitalia]], [[DHT]] develops the external [[male genitalia]]. Children with [[5-alpha reductase]] [[deficiency]] suffers from defective [[external genitalia]] and [[ambiguous genitalia]].
==Pathophysiology==
==Pathophysiology==
'''[[5-alpha-reductase]]''' is an [[enzyme]] that converts [[testosterone]] to [[dihydrotestosterone]] (DHT) in peripheral tissues. 5-alpha-reductase deficiency-2 is biochemically characterized by low to low normal levels of testosterone and decreased levels of 5α-DHT, creating a higher testosterone/DHT ratio.
'''[[5-alpha-reductase]]''' is an [[enzyme]] that converts [[testosterone]] to [[dihydrotestosterone]] (DHT) in peripheral tissues. 5-alpha-reductase deficiency-2 is biochemically characterized by low to low normal levels of testosterone and decreased levels of 5α-DHT, creating a higher testosterone/DHT ratio.

Latest revision as of 21:35, 23 December 2021

5-alpha-reductase deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating 5-alpha-reductase deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Molecular Genetic Studies

Genotyping

Pelvic X Ray

CT

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

5-alpha-reductase deficiency pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of 5-alpha-reductase deficiency pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on 5-alpha-reductase deficiency pathophysiology

CDC on 5-alpha-reductase deficiency pathophysiology

5-alpha-reductase deficiency pathophysiology in the news

Blogs on 5-alpha-reductase deficiency pathophysiology

Directions to Hospitals Treating 5-alpha-reductase deficiency

Risk calculators and risk factors for 5-alpha-reductase deficiency pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

The 5-alpha reductase enzyme is responsible for converting testosterone to dihydrotestosterone (DHT) which is a more potent form playing major roles in male sexual development. While Testosterone leads the development of internal male genitalia, DHT develops the external male genitalia. Children with 5-alpha reductase deficiency suffers from defective external genitalia and ambiguous genitalia.

Pathophysiology

5-alpha-reductase is an enzyme that converts testosterone to dihydrotestosterone (DHT) in peripheral tissues. 5-alpha-reductase deficiency-2 is biochemically characterized by low to low normal levels of testosterone and decreased levels of 5α-DHT, creating a higher testosterone/DHT ratio.

Biochemical effects of 5-alpha-reductase deficiency-2 in testosterone biosynthesis. Typically levels of testosterone are elevated, while levels of DHT are significantly decreased, leading to male undervirilization.

DHT is a potent androgen, necessary for the development of male external genitalia in utero.

References

Template:WH Template:WS